Related Experiment Videos
[Adverse reactions and quality of life]
1Departamento de Gastroenterología, Hospital de Especialidades del Centro Médico Nacional Siglo XXI, IMSS. Ave. Cuauhtémoc No. 330, Col. Doctores, Deleg. Cuauhtémoc, 06720 México, D.F.
Insights
Chronic hepatitis C significantly impacts quality of life, regardless of disease severity. Eliminating the hepatitis C virus (HCV) improves life quality, with pegylated interferon showing promising results.
Area of Science:
- Hepatology
- Virology
- Clinical Medicine
Context:
- Chronic hepatitis C virus (HCV) infection is a global health concern.
- Patient-reported outcomes, including quality of life (QoL), are crucial in assessing treatment efficacy.
- Previous treatments like interferon monotherapy or combination therapy with ribavirin have shown limitations.
Purpose:
- To evaluate the impact of chronic hepatitis C on patient quality of life.
- To compare the QoL outcomes of different interferon-based therapies for HCV.
- To assess the effect of viral elimination on QoL in chronic hepatitis C patients.
Summary:
- Chronic hepatitis C negatively affects quality of life, irrespective of liver disease severity.
- Treatment with interferon or interferon plus ribavirin can exacerbate QoL issues due to adverse reactions.
- Pegylated interferon demonstrates superior QoL outcomes during and after treatment compared to standard interferon or interferon plus ribavirin.
Impact:
- Hepatitis C treatment significantly influences patient well-being and daily functioning.
- Pegylated interferon offers a potential therapeutic option for improving QoL in chronic hepatitis C patients.
- Understanding QoL impacts is essential for comprehensive hepatitis C management and patient-centered care.
Abstract:
Several studies evaluated the impact of chronic hepatitis C on the patient's quality of life. The findings show that chronic HCV infection affects life quality, independently of the severity of the hepatitis. Quality of life improves when the virus is eliminated. Adverse reactions of the monotherapy with interferon or combination therapy with ribavirin can be added to the debilitating effects of the disease itself. Impact on the quality of life may be even greater with a program that includes frequent doses of standard interferon. Preliminary data, reported as abstracts and as complete documents, suggest that pegylated interferon has better results during and after treatment as far as quality of life is concerned. The comparison was made with interferon a2a alone and with interferon a2b plus ribavirin.